Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib plus stereotactic radiotherapy for symptomatic brain metastases in EGFR-mutant NSCLC
ChiCTR2600134210Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) and brain metastases (2 cohorts), sponsored by Sichuan Cancer Hospital. Primary endpoint: Intracranial progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600134210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134210.